Nuzzo Silvia, Roscigno Giuseppina, Affinito Alessandra, Ingenito Francesco, Quintavalle Cristina, Condorelli Gerolama
IRCCS SDN, 80143 Naples, Italy.
Department of Molecular Medicine and Medical Biotechnology, "Federico II" University of Naples, Via Pansini 5, 80131 Naples, Italy.
Cancers (Basel). 2019 Oct 10;11(10):1521. doi: 10.3390/cancers11101521.
Due to the progress made in the area of precision and personalized medicine in the field of cancer therapy, strategies to selectively and specifically identify target molecules causative of the diseases are urgently needed. Efforts are being made by a number of different laboratories, companies, and researchers to develop therapeutic molecules that selectively recognize the tissues and the cells of interest, exhibit few or no off-target and side effects, are non-immunogenic, and have a strong action. Aptamers, artificially selected single-stranded DNA or RNA oligonucleotides, are promising molecules satisfying many of the requirements needed for diagnosis and precision medicine. Aptamers can also couple to their native mechanism of action the delivery of additional molecules (oligonucleotides, siRNAs, miRNAs) to target cells. In this review, we summarize recent progress in the aptamer-mediated strategy for the specific delivery of therapeutic oligonucleotides.
由于癌症治疗领域在精准和个性化医学方面取得的进展，迫切需要能够选择性且特异性地识别导致疾病的靶分子的策略。许多不同的实验室、公司和研究人员正在努力开发能够选择性识别感兴趣的组织和细胞、几乎没有或没有脱靶效应和副作用、无免疫原性且具有强大作用的治疗性分子。适体是人工选择的单链DNA或RNA寡核苷酸，是满足诊断和精准医学所需许多要求的有前景的分子。适体还可以将额外分子（寡核苷酸、小干扰RNA、微小RNA）递送至靶细胞，并结合其天然作用机制。在本综述中，我们总结了适体介导的治疗性寡核苷酸特异性递送策略的最新进展。
